JP7665529B2 - ジアミノピリミジン化合物を使用することによって咳を治療する方法 - Google Patents

ジアミノピリミジン化合物を使用することによって咳を治療する方法 Download PDF

Info

Publication number
JP7665529B2
JP7665529B2 JP2021564189A JP2021564189A JP7665529B2 JP 7665529 B2 JP7665529 B2 JP 7665529B2 JP 2021564189 A JP2021564189 A JP 2021564189A JP 2021564189 A JP2021564189 A JP 2021564189A JP 7665529 B2 JP7665529 B2 JP 7665529B2
Authority
JP
Japan
Prior art keywords
days
body weight
cough
compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530890A (ja
JP2022530890A5 (cg-RX-API-DMAC7.html
Inventor
ヤンピン チャオ,
ホンジュン ワン,
ファイ ファン,
ユアンユアン ジアン,
フイニン リャン,
ラン アン,
チョウ ラン,
ジン ワン,
リイン チョウ,
ヤンアン リウ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of JP2022530890A publication Critical patent/JP2022530890A/ja
Publication of JP2022530890A5 publication Critical patent/JP2022530890A5/ja
Application granted granted Critical
Publication of JP7665529B2 publication Critical patent/JP7665529B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021564189A 2019-04-30 2020-04-29 ジアミノピリミジン化合物を使用することによって咳を治療する方法 Active JP7665529B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085180 2019-04-30
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (3)

Publication Number Publication Date
JP2022530890A JP2022530890A (ja) 2022-07-04
JP2022530890A5 JP2022530890A5 (cg-RX-API-DMAC7.html) 2023-05-11
JP7665529B2 true JP7665529B2 (ja) 2025-04-21

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564189A Active JP7665529B2 (ja) 2019-04-30 2020-04-29 ジアミノピリミジン化合物を使用することによって咳を治療する方法

Country Status (12)

Country Link
US (1) US20220211703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3960179B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665529B2 (cg-RX-API-DMAC7.html)
KR (1) KR102935436B1 (cg-RX-API-DMAC7.html)
CN (1) CN114007619B (cg-RX-API-DMAC7.html)
AU (1) AU2020265327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021600A2 (cg-RX-API-DMAC7.html)
ES (1) ES3067370T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021013338A (cg-RX-API-DMAC7.html)
SG (1) SG11202111877TA (cg-RX-API-DMAC7.html)
TW (1) TWI736243B (cg-RX-API-DMAC7.html)
WO (1) WO2020221274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508445A (ja) 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2019510025A (ja) 2016-03-25 2019-04-11 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2021501184A (ja) 2017-11-01 2021-01-14 ベイジン タイド ファーマシューティカル カンパニー リミテッドBeijing Tide Pharmaceutical Co., Ltd. P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
DK2343281T3 (en) 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508445A (ja) 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2019510025A (ja) 2016-03-25 2019-04-11 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2021501184A (ja) 2017-11-01 2021-01-14 ベイジン タイド ファーマシューティカル カンパニー リミテッドBeijing Tide Pharmaceutical Co., Ltd. P2x3及び/又はp2x2/3受容体アンタゴニスト、それを含む医薬組成物及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUR. J. MED. CHEM. -CHIMICA THERAPEUTICA,1977年,12(6),531-536
Lancet,2015年,385,1198-205

Also Published As

Publication number Publication date
ES3067370T3 (en) 2026-05-21
JP2022530890A (ja) 2022-07-04
KR102935436B1 (ko) 2026-03-05
SG11202111877TA (en) 2021-11-29
MX2021013338A (es) 2022-01-24
BR112021021600A2 (pt) 2022-01-04
TWI736243B (zh) 2021-08-11
EP3960179A1 (en) 2022-03-02
KR20220007620A (ko) 2022-01-18
US20220211703A1 (en) 2022-07-07
AU2020265327A1 (en) 2021-12-16
CN114007619B (zh) 2024-08-06
EP3960179B1 (en) 2026-03-18
CN114007619A (zh) 2022-02-01
TW202106302A (zh) 2021-02-16
EP3960179A4 (en) 2023-01-25
CA3138780A1 (en) 2020-11-05
AU2020265327B2 (en) 2025-09-11
WO2020221274A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
TWI804743B (zh) 治療特發性肺纖維化的方法
JP7663508B2 (ja) ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法
EP3960179B1 (en) Method for treating cough by using diaminopyrimidine compound
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
EP4591863A1 (en) Method for treating pneumoconiosis
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40062124B (en) Method for treating cough by using diaminopyrimidine compound
CA3138780C (en) Method for treating cough by using diaminopyrimidine compound
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40063168B (en) Method for treating cough by using diaminopyrimidine compound
HK40121343A (en) Method for treating idiopathic pulmonary fibrosis
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211213

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250409

R150 Certificate of patent or registration of utility model

Ref document number: 7665529

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150